Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
In: Journal of Hematology & Oncology, Jg. 15 (2022-12-01), Heft 1
Online
academicJournal
Zugriff:
Titel: |
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
|
---|---|
Autor/in / Beteiligte Person: | Zhang, Guangbing ; Guo, Cuiyu ; Wang, Yan ; Zhang, Xianda ; Liu, Shuang ; Qu, Wen ; Chen, Chunxia ; Yan, Lingli ; Yang, Zhouning ; Zhang, Zhixiong ; Jiang, Xiaohua ; Chen, Xiaofeng ; Liu, Hong ; Lai, Qinhuai ; Wei, Xian ; Lu, Ying ; Zhao, Shengyan ; Deng, Han ; Wang, Yuxi ; Yu, Lin ; Yu, Hongbin ; Wu, Yu ; Su, Zhaoming ; Chen, Pengyu ; Ren, Ziqing ; Yu, Meng ; Qu, Feng ; Luo, Yong ; Gou, Lantu ; Li, Qing ; Huang, Ying ; Ma, Fanxin ; Yang, Jinliang |
Link: | |
Zeitschrift: | Journal of Hematology & Oncology, Jg. 15 (2022-12-01), Heft 1 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 1756-8722 (print) |
DOI: | 10.1186/s13045-022-01395-0 |
Sonstiges: |
|